DENTSPLY SIRONA Inc. (XRAY - Free Report) recently announced preliminary results for fourth-quarter 2018 wherein the top line surpassed the Zacks Consensus Estimate of $1.02 billion.
Revenues totaled at $1.06 billion, showing a fall of 2.9% year over year.
Adjusted earnings per share came in at 58 cents, beating the Zacks Consensus Estimate of 54 cents. Earnings declined 29.3% year over year.
DENTSPLY’s preliminary fourth-quarter 2018 results seem to impress investors. Share price of this Zacks Rank #3 (Hold) stock rose 4.6% to close at $49.13 since the release.
In the past year, shares of DENTSPLY have declined 12.1%, comparing favorably with the industry's 1.3% fall. The current level is also lower than the S&P 500’s rally of 3.3%.
Revenues in 2018 are expected at $4 billion, surpassing the Zacks Consensus Estimate of $3.94 billion. Revenues fell 0.2% from 2017.
Earnings per share for 2018 were $2.01, beating the Zacks Consensus Estimate of $1.97. The figure dropped 24.4% from 2017.
Revenues in the fourth quarter are expected to see solid year-over-year increase of 4.6% in Europe and 1.4% in rest of the world. However, U.S. revenues declined 14.7% on a year-over-year basis in the quarter.
Fourth-quarter Consumable revenues increased 3.4% year over year. Notably, the segment benefited from a recovery in shipment levels at the company’s European distribution center in Venlo, the Netherlands.
Technology & Equipment revenues declined 7.4% year over year.
For 2019, DENTSPLY expects adjusted earnings per share within the range of $2.25-$2.40. The mid-point of $2.32 of the guided range lies above the Zacks Consensus Estimate of $2.15.
However, portfolio initiatives are expected to negatively impact 2019 revenues.
Some better-ranked stocks in the broader medical space are Abbott Laboratories (ABT - Free Report) , Merit Medical Systems, Inc. (MMSI - Free Report) and Surmodics, Inc. (SRDX - Free Report) .
Abbott’s long-term earnings growth rate is projected at 11.7%. The stock has a Zacks Rank #2 (Buy).
Merit Medical’s long-term earnings growth rate is projected at 13%. The stock has a Zacks Rank #2.
Surmodics’ long-term earnings growth rate is expected at 10%. The stock flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, wouldn't you like to know about our 10 finest buy-and-holds for the year?
From more than 4,000 companies covered by the Zacks Rank, these 10 were picked by a process that consistently beats the market. Even during 2018 while the market dropped -5.2%, our Top 10s were up well into double-digits. And during bullish 2012 – 2017, they soared far above the market's +126.3%, reaching +181.9%.
This year, the portfolio features a player that thrives on volatility, an AI comer, and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs.
See Stocks Today >>